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midlife glucose levels and reducing incipient risk of
dementia. Although Cintosun and colleagues note that a
large number of participants and the ability to follow
them for up to 4 decades strengthened our observational
study, they present some methodological concerns,
which we would like to address. We do not claim to
make any causal inferences about random measured
blood glucose levels and dementia-related death but
point to a clear risk association. Cintosun and col-
leagues do not mention that we adjusted for education
(related to socioeconomic status) and cardiovascular dis-
orders but were unable to include data on hospitaliza-
tions. Adjusting for relevant confounders is important,
but we do not view it likely that factors such as vitamin
deficiencies or thyroid disorders would alter the associa-
tion between glucose level and dementia-related death,
as Cintosun and colleagues suggest. We performed a
wide assessment with variables such as depressive symp-
toms, anxiety, and alcohol, including a sensitivity analy-
sis restricting the follow-up to the age of 65 (early-onset
dementia), and the results did not differ to a significant
degree. Although the above-mentioned factors are
deemed independent risk factors of dementia, their
importance when evaluating high glucose levels and
dementia-related death is uncertain. In response to Cin-
tosun’s concern regarding the use of dementia-related
death, we included all registered deaths with dementia
on the death certificate as the underlying or accompany-
ing cause, and in understanding the mechanism of
cause-specific dementia mortality, the use of dementia-
related death as an outcome in observational studies is
considered valid.3 Furthermore, a validation study of
Norwegian death certificates in dementia in nursing
home residents showed high specificity.4 Using data
from a large case–control study of dementia-related
death (n = 561), we found that the risk of dementia-
related death in individuals with various apolipoprotein
E genotypes were comparable with risk ratios from
studies using clinical diagnoses as the end point, sug-
gesting that dementia-related death could prove useful
as a proxy for clinical dementia diagnoses in epidemio-
logical studies.5
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DEPRESCRIBING STATINS—IS IT ETHICAL?
To the Editor: I believe that Gnjidic and colleagues1 may
not have given a fair account of the benefits of statin treat-
ment in older adults. In a population-based study, they did
not find significantly less dementia in statin users (although
point estimate was clearly below unity) but nevertheless
noted significantly lower mortality in statin users than
nonusers. The totality of the evidence in older adults, and
even in frail individuals and those with multimorbidity,
supports this finding.2–4 Gnjidic and colleagues may also
have misinterpreted the review of Desai and colleagues5 by
stating that there is growing evidence of adverse effects of
statins.
Why “growing”? The possibility of adverse effects on
muscle has been known since statins were introduced, and
to the best of my knowledge, nothing new has emerged,
except that statins do not cause all muscle aches during
statin treatment.6 The possibility of diabetes mellitus is a
more recently recognized adverse effect, but the clinical
significance of statin-associated diabetes mellitus is
unknown because, paradoxically, statin treatment
improves the prognosis of individuals with diabetes melli-
tus.7 There is a list of conditions linked to statin use, such
as cataract and erectile dysfunction, but results are incon-
sistent, and confounding by indication cannot usually be
excluded.8 Alternatively, other potential benefits such as
fewer complications from venous thromboembolism, less
pancreatitis, less chronic obstructive pulmonary disease–re-
lated mortality, and lower prostate cancer–specific mortal-
ity5,9 have emerged, but these possibilities have received
much less attention.
Given the lower mortality of older statin users in
many studies, including the study of Gnjidic and col-
leagues,1 is it ethical to suggest trials—for individuals who
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are not in a terminal stage—in which statins are depre-
scribed?
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RESPONSE TO TIMO E. STRANDBERG
To the Editor: We thank Professor Strandberg1 for his
valuable comments and interest in our recently published
letter to the editor.2 The aim of our study was to deter-
mine associations between statin use and incident dementia
according to disease severity and multimorbidity, but since
the publication of our letter, a new Cochrane review has
shed additional light on the topic.3 This Cochrane review
concludes that current evidence does not support the role
of statins for prevention of dementia, which is in agree-
ment with our study findings.
Ensuring rational statin use in older adults is challeng-
ing because clinical trial data in older adults with multimor-
bidity and polypharmacy are limited. In addition, as people
age, treatment goals may change from extending duration of
life to maintaining function and quality of life.4 Therefore,
more research is warranted to generate information about
benefits and side effects of statins in real-world data from
older adults. Research into deprescribing medications is an
emerging area and requires robust evidence to inform clini-
cal decisions.5 The need for evidence-based deprescribing
guidelines for a range of medication classes including statins
was highlighted in a recent Delphi process.6
We appreciate Professor Strindberg’s comments, and
we support more research efforts to inform rational drug
prescribing for older adults worldwide.
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